In patients with hormone receptor-positive (HRpos), human epidermal growth factor receptor 2-negative (HER2neg) early-stage breast cancer, prognosis prediction has been applied to determine which patients should be treated with chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.